Side-by-side comparison of AI visibility scores, market position, and capabilities
Zimmer Biomet (ZBH) reported ~$7.7B revenue in FY2024. Leading maker of orthopedic implants for knee and hip replacement surgeries, with robotics and digital surgery platforms. HQ: Warsaw, IN.
Zimmer Biomet Holdings, Inc. is one of the world's largest musculoskeletal healthcare companies, designing, manufacturing, and distributing orthopedic implants, spinal devices, dental implants, and surgical instrumentation. The company's core products are total knee and total hip replacement systems — the implants that allow surgeons to replace arthritic or damaged joints, enabling millions of patients to regain mobility and reduce chronic pain. Formed through Zimmer Holdings' $13.4 billion acquisition of Biomet in 2015, the company serves over 25 million patients annually.
mRNA pioneer with $3.2B FY2024 revenue (down from $18.4B 2022 COVID peak); mRESVIA RSV vaccine approved 2024; personalized cancer vaccine with Merck shows 44% recurrence reduction in melanoma.
Moderna is a clinical-stage biotechnology company that pioneered the development of messenger RNA (mRNA) therapeutics and vaccines, founded in 2010 by Noubar Afeyan, Robert Langer, Kenneth Chien, Stéphane Bancel, and others in Cambridge, Massachusetts, where it is headquartered and trades on Nasdaq (MRNA). The company achieved extraordinary commercial success with Spikevax, its COVID-19 mRNA vaccine developed in partnership with the U.S. government in 2020—generating $18.4 billion in COVID vaccine revenues in 2022 at peak—before experiencing a severe revenue decline as global COVID booster demand normalized. For FY2024, Moderna generated approximately $3.2 billion in revenues, with Spikevax and the reformulated XBB.1.5-targeting COVID vaccine contributing the majority, while the company's significant R&D investment pipeline consumed most operating cash flows.
Zimmer Biomet vs
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.